If not administered properly, health experts say medications like Ozempic, Mounjaro, and Wegovy can cause gastrointestinal ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

Many younger patients aren't prepared for the physical changes that follow GLP-1 weight loss, and they're increasingly turning to cosmetic surgery to address issues such as sagging skin.

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

In the second instalment of a two-part feature on captive health insurance in the US, Diana Bui explores how this model can ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...